MYC and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, tigecycline has been shown to impair mitochondrial translation in various blood malignancies and solid neoplasms such as AML [22,65], CML [33], diffuse large B-cell lymphoma [30], Myc-driven lymphomas [37], Burkitt’s lymphoma [22], renal cell carcinoma [42], and ovarian cancer [39].